214 related articles for article (PubMed ID: 29773603)
1. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with
Ding YY; Stern JW; Jubelirer TF; Wertheim GB; Lin F; Chang F; Gu Z; Mullighan CG; Li Y; Harvey RC; Chen IM; Willman CL; Hunger SP; Li MM; Tasian SK
Haematologica; 2018 Sep; 103(9):e427-e431. PubMed ID: 29773603
[No Abstract] [Full Text] [Related]
2. Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion.
Chen X; Yuan L; Zhou J; Wang F; Zhang Y; Ma X; Cao P; Fang J; Chen J; Zhou X; Wu Q; Liu M; Liu H
Genes Chromosomes Cancer; 2022 Jan; 61(1):55-58. PubMed ID: 34418218
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
4. Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.
Chen X; Wang F; Zhang Y; Ma X; Liu M; Cao P; Zhou L; Wang L; Zhang X; Wang T; Liu H
Mol Genet Genomic Med; 2020 Mar; 8(3):e1110. PubMed ID: 31885183
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
[TBL] [Abstract][Full Text] [Related]
6. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
7. New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Saini L; Brandwein J
Curr Hematol Malig Rep; 2017 Apr; 12(2):136-142. PubMed ID: 28243848
[TBL] [Abstract][Full Text] [Related]
8. Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.
Francke S; Mies A; Meggendorfer M; Oelschlaegel U; Balaian E; Gloaguen S; Haferlach T; Ehninger G; Bornhäuser M; Platzbecker U
Leuk Lymphoma; 2017 May; 58(5):1271-1272. PubMed ID: 27659716
[No Abstract] [Full Text] [Related]
9. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R
Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250
[TBL] [Abstract][Full Text] [Related]
10. JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).
Hatta Y; Hayakawa F; Yamazaki E
Int J Hematol; 2020 Oct; 112(4):439-458. PubMed ID: 32812190
[No Abstract] [Full Text] [Related]
11. A life-threatening ruxolitinib discontinuation syndrome.
Coltro G; Mannelli F; Guglielmelli P; Pacilli A; Bosi A; Vannucchi AM
Am J Hematol; 2017 Aug; 92(8):833-838. PubMed ID: 28457008
[No Abstract] [Full Text] [Related]
12. Philadelphia chromosome-positive Acute Lymphoblastic Leukemia.
Forghieri F; Luppi M; Potenza L
Hematology; 2015 Dec; 20(10):618-9. PubMed ID: 26574786
[No Abstract] [Full Text] [Related]
13. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
14. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols.
Ribera JM; García O; Fernández-Abellán P; Lavilla E; Bernal MT; González-Campos J; Brunet S; Monteserín MC; Montesinos P; Sarrá J; Calbacho M; Alvarez-Larrán A; Tormo M; Oriol A;
Br J Haematol; 2012 Nov; 159(4):485-8. PubMed ID: 22966847
[No Abstract] [Full Text] [Related]
15. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
[TBL] [Abstract][Full Text] [Related]
16. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
Yilmaz M; Kantarjian H; Ravandi-Kashani F; Short NJ; Jabbour E
Clin Adv Hematol Oncol; 2018 Mar; 16(3):216-223. PubMed ID: 29742077
[TBL] [Abstract][Full Text] [Related]
17. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.
Wells J; Jain N; Konopleva M
Clin Adv Hematol Oncol; 2017 Jul; 15(7):554-561. PubMed ID: 28749919
[TBL] [Abstract][Full Text] [Related]
18. Amplification of BCR-ABL rearrangement in atypical Philadelphia chromosome: a new variant detected by fluorescence in situ hybridization in one case of acute lymphoblastic leukemia.
Poulain S; Daudignon A; Le Baron F; Bisiau H; Simon M; Duthilleul P
Cancer Genet Cytogenet; 1999 Jan; 108(2):158-61. PubMed ID: 9973946
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
[TBL] [Abstract][Full Text] [Related]
20. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
